You are using an outdated browser. Please upgrade your browser to improve your experience.

You are using an outdated browser.

To ensure optimal security, this website will soon be unavailable on this browser. Please upgrade your browser to allow continued use of ACP websites.

Hepatitis C Ribonucleic Acid (RNA) Testing Before Initiating Treatment

Percentage of patients aged 18 years and older with a diagnosis of chronic hepatitis C who are receiving antiviral treatment for whom quantitative HCV RNA testing was performed within 6 months prior to initiation of antiviral treatment (paired with NQF 0396)

Date Reviewed: July 26, 2014

Measure Info

NQF 0395CMS 84NQF Endorsement Removed
Measure Type: 
Process
Measure Steward: 
American Gastroenterological Association
Clinical Topic Area: 
Hepatitis C

Care Setting: 
Outpatient
Data Source: 
Electronic Health Data
Electronic Health Records
Registry

ACP does not support NQF 0395: “Hepatitis C Ribonucleic Acid (RNA) Testing Before Initiating Treatment.” Although this practice represents the standard of care, the evidence presented in support of the measure shows a very small gap in care (about 10%), which could be explained by error in data collection. The small potential benefit is outweighed by the burden of measurement.